Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression.


OBJECTIVES About 50% of patients with unipolar depression suffer from treatment-resistant depression (TRD). Animal studies have suggested potential antidepressant properties of valproate (VPA) possibly due to its implication in epigenetic programming. METHODS Fourteen TRD patients (seven males and seven females; age 19-59) received VPA (375-1000 mg/day… (More)
DOI: 10.3109/15622975.2015.1073856